1-苄基-3-羟甲基-3-Boc-氨基吡咯烷 | 475469-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-3-羟甲基-3-Boc-氨基吡咯烷
• 中文别名: 1-苄基-3-羟甲基-3-叔丁氧羰基氨基吡咯烷；1-苄基3-羟甲基-3-BOC-氨基吡咯烷
• 英文名称: 1-benzyl-3-N-tert-butoxycarbonylamino-3-hydroxymethylpyrrolidine
• 英文别名: Tert-butyl 1-benzyl-3-(hydroxymethyl)pyrrolidin-3-ylcarbamate；tert-butyl N-[1-benzyl-3-(hydroxymethyl)pyrrolidin-3-yl]carbamate
• CAS: 475469-14-8
• 化学式: C₁₇H₂₆N₂O₃
• 分子量: 306.405
• InChiKey: YAJSWXXRXAAIHN-UHFFFAOYSA-N

物化性质

• 沸点：
  419.3±40.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-苄基-3-羟甲基-3-Boc-氨基吡咯烷 在 5percent Pd/C 氢气 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 (3-羟甲基吡咯烷-3-基)氨基甲酸叔丁酯
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1

  摘要：

  In an attempt to search for clinically useful antitumor agents, we have discovered that a series of 1,1-disubstituted-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids possessed moderate cytotoxic activity.,We investigated the structure-activity relationships in this series of compounds by changing N-1 and C-7 positions and the core ring structure itself and evaluated the synthesized compounds against several murine and human tumor cell lines. These modifications led us to the following findings. (1) The 2-thiazolyl group at the N-1 position of the naphthyridine structure is the best substituent for antitumor activity. (2) Regarding core ring structure, the naphthyridine derivative is the most active followed by pyridopyrimidine analogue. (3) At the C-7 position, -aminopyrrolidine derivatives are more effective than other amines or thioether derivatives. Finally, the trans-3-amino-4-methoxypyrrolidinyl derivative (43j), and the 3-amino-3-methylpyrrolidinyl derivative (43f) as well as 3-aminopyrrolidinyl derivative (AT-3639, 1) were determined to be effective in in vitro and in vivo antitumor assays, and their activity was comparable to that of etoposide.

  DOI：

  10.1021/jm010057b
• 作为产物：
  描述：

  1-苄基-3-氨基吡咯烷-3-甲酸 在 盐酸 、 红铝 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 7.0h， 生成 1-苄基-3-羟甲基-3-Boc-氨基吡咯烷
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1

  摘要：

  In an attempt to search for clinically useful antitumor agents, we have discovered that a series of 1,1-disubstituted-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids possessed moderate cytotoxic activity.,We investigated the structure-activity relationships in this series of compounds by changing N-1 and C-7 positions and the core ring structure itself and evaluated the synthesized compounds against several murine and human tumor cell lines. These modifications led us to the following findings. (1) The 2-thiazolyl group at the N-1 position of the naphthyridine structure is the best substituent for antitumor activity. (2) Regarding core ring structure, the naphthyridine derivative is the most active followed by pyridopyrimidine analogue. (3) At the C-7 position, -aminopyrrolidine derivatives are more effective than other amines or thioether derivatives. Finally, the trans-3-amino-4-methoxypyrrolidinyl derivative (43j), and the 3-amino-3-methylpyrrolidinyl derivative (43f) as well as 3-aminopyrrolidinyl derivative (AT-3639, 1) were determined to be effective in in vitro and in vivo antitumor assays, and their activity was comparable to that of etoposide.

  DOI：

  10.1021/jm010057b

文献信息

• [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE PIM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2012154274A1

  公开（公告）日：2012-11-15

  Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

  式I的化合物：其中R1、R2、R3、R4和R10的含义如规范中所述，在通过PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病治疗中有用的受体酪氨酸激酶抑制剂。
• AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Corbett Stephen Matthew

  公开号：US20080051419A1

  公开（公告）日：2008-02-28

  The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R 1 , R 2 , R 5 , R 6 , L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of making the compounds of formula I.

  本发明涉及化合物I的公式，或其药学上可接受的盐，其中A是以下公式的基团： 同时还涉及其药学上可接受的盐和溶剂，其中X、Z、D、E、V、W、Y、R1、R2、R5、R6、L和u的定义如本文所述。 本发明还涉及通过向需要该化合物的患者施用化合物I来治疗哺乳动物中的异常细胞生长的方法，以及含有化合物I的用于治疗此类疾病的组合物。 本发明还涉及制备化合物I的方法。
• Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264428A1

  公开（公告）日：2009-10-22

  Described are compounds of the formula (I) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

  本文描述了一种公式（I）的化合物，其具有口服活性并能结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。还描述了在需要改善或治疗天冬氨酸蛋白酶相关疾病的受试者中使用本文所述化合物的方法。
• RENIN INHIBITORS
  申请人：Baldwin John J.

  公开号：US20090275581A1

  公开（公告）日：2009-11-05

  Disclosed are compounds according to Formula I: wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

  本发明涉及公式I所示的化合物，其中变量在此定义。这些化合物能够结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。本发明还描述了拮抗需要受到天冬氨酸蛋白酶抑制剂的受试者的方法，包括向受试者施用公式I所示的化合物的治疗有效量。
• Triazolopyridine compounds as PIM kinase inhibitors
  申请人：Blake James F.

  公开号：US08889704B2

  公开（公告）日：2014-11-18

  Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

  公式I的化合物：其中R1、R2、R3、R4和R10具有规范中给出的含义，是在治疗由PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病中有用的受体酪氨酸激酶抑制剂。